<DOC>
	<DOCNO>NCT02222493</DOCNO>
	<brief_summary>The study ass efficacy safety PF-06438179 infliximab combination methotrexate subject active rheumatoid arthritis inadequate response methotrexate .</brief_summary>
	<brief_title>A Study PF-06438179 ( Infliximab-Pfizer ) Infliximab Combination With Methotrexate Subjects With Active Rheumatoid Arthritis ( REFLECTIONS B537-02 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis base 2010 ACR/EULAR criterion least 4 month . At least 6 tender ( 68 assess ) 6 swollen ( 66 assess ) joint screen baseline . HSCRP equal great 10 mg/L . Must receive methotrexate least 12 week stable dose least 4 week . Evidence untreated inadequately treated latent active TB . Evidence history moderate severe heart failure ( NYHA Class III/IV ) Infection require hospitalization parenteral antimicrobial therapy judge clinically significant investigator within 6 month prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>infliximab</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>